EP Patent

EP3658194A1 — Dual mode radiotracer and -therapeutics

Assigned to Technische Universitaet Muenchen · Expires 2020-06-03 · 6y expired

What this patent protects

The present invention relates to a ligand-SIFA-chelating conjugate, comprising, within a single molecule, three distinct fractions: (a) one or more ligands that are capable of binding to a target molecule relevant to a disease, ( b) an acceptor moiety of silicon fluoride (SIFA) w…

USPTO Abstract

The present invention relates to a ligand-SIFA-chelating conjugate, comprising, within a single molecule, three distinct fractions: (a) one or more ligands that are capable of binding to a target molecule relevant to a disease, ( b) an acceptor moiety of silicon fluoride (SIFA) which comprises a covalent bond between a silicon atom and a fluorine atom, and (c) one or more chelating groups, optionally containing a non-radioactive or radioactive chelate cation.

Drugs covered by this patent

Patent Metadata

Patent number
EP3658194A1
Jurisdiction
EP
Classification
—
Expires
2020-06-03
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.